Management of acute decompensated heart failure in an evidence-based era: What is the evidence behind the current standard of care?

详细信息    查看全文

• 作者：Wassim H. Fares
• 刊名：Heart Lung: The Journal of Acute and Critical Care
• 出版年：2008
• 出版时间：May-June 2008
• 年：2008
• 卷：37
• 期：3
• 页码：173-178
• 全文大小：573 K

文摘

Despite the increased mortality and morbidity in patients with acute decompensated heart failure (ADHF), its management has been based primarily on anecdotal experiences and physiologic assumptions rather than on prospective randomized controlled trials. The data on diuretics have been conflicting. Routine use of inotropes in ADHF has been clearly associated with increased mortality and morbidity, although inotropes seem to cause short-term clinical improvement. The safety of the different vasoactive medications has never been adequately confirmed in prospective trials despite their use for a long time in heart failure. Good evidence that supports the safety and efficacy of the different medications that are routinely used in ADHF is lacking. Unless properly designed prospective clinical trials are done to evaluate the safety of the various ADHF regimens, clinicians might continue to be misguided by the beneficial short-term effects at the expense of long-term mortality and morbidity.